1990-90-5

Basic information

• Product Name: 3-Methyl-4-aminopyridine
• Synonyms: 3-METHYLPYRIDIN-4-AMINE;3-METHYL-PYRIDIN-4-YLAMINE;3-METHYL-4-AMINOPYRIDINE;3-METHYL-4-PYRIDINYLAMINE;4-AMINO-3-METHYLPYRIDINE;4-AMINO-3-PICOLINE;3-methyl-4-pyridinamin;4-amino-3-picolin
• CAS NO: 1990-90-5
• Molecular Formula: C₆H₈N₂
• Molecular Weight: 108.14
• EINECS: 217-872-5
• Product Categories: VARIOUSAMINE;Pyridine;Amines;Pyridines;Pyridines derivates;Boronic Acid;Pyridine Series
• Mol File: 1990-90-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 106-107
• Boiling Point: 192.78°C (rough estimate)
• Flash Point: 138.4 °C
• Appearance: /
• Density: 0.9581 (rough estimate)
• Vapor Pressure: 0.00918mmHg at 25°C
• Refractive Index: 1.5400 (estimate)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: pK1: 9.43(+1) (25°C)
• CAS DataBase Reference: 3-Methyl-4-aminopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-4-aminopyridine(1990-90-5)
• EPA Substance Registry System: 3-Methyl-4-aminopyridine(1990-90-5)

Safety Data

• Hazard Codes: C,Xi,Xn
• Statements: 23/24/25-36/37/38-34-22-20/21/22
• Safety Statements: 22-36/37/39-45-36-27-26
• RIDADR: 2811
• RTECS: TJ5140000
• Hazardous Substances Data: 1990-90-5(Hazardous Substances Data)

Usage

Chemical Properties

Crystals

Uses

4-Amino-3-methylpyridine is a non depolarizing muscular relaxant with antagonist effect that functions on neuromuscular transmission and in central nervous systems in rats. A central cholinergic agent.

Safety Profile

Moderately toxic by ingestion.When heated to decomposition it emits toxic fumes ofNOx.

InChI:InChI=1/C6H8N2/c1-5-4-8-3-2-6(5)7/h2-4H,1H3,(H2,7,8)

Upstream product

• 104915-66-4 N-(3-methylpyridin-4-yl)acetamide 
• 108-99-6 3-Methylpyridine 
• 86847-73-6 2,2-Dimethyl-N-(3-methyl-4-pyridinyl)propanamide 
• 109127-89-1 1,7-dimethyl-2-(4-nitro-phenyl)-1,2-dihydro-pyrazolo[4,3-c]pyridin-3-one 
• 110178-76-2 1,7-dimethyl-2-phenyl-1,2-dihydro-pyrazolo[4,3-c]pyridin-3-one 
• 1003-73-2 3-picoline-N-oxide 
• 1074-98-2 3-methyl-4-nitropyridine N-oxide 
• 1678-53-1 4-nitro-3-methylpyridine 
• 100383-06-0 4-amino-5-methyl-nicotinic acid 

Downstream Products

• 18227-67-3 4-amino-3-methyl-5-nitropyridine 
• 18232-91-2 4,5-diamino-6-chloro-3-methylpyridine 
• 515815-09-5 2'-deoxy-3',5'-di-O-p-toluoyl-7-chloro-4-methyl-1-β-D-ribofuranosyl-3(H)-imidazo[4,5-c]pyridine 
• 515815-10-8 2'-deoxy-3',5'-di-O-p-toluoyl-4-chloro-7-methyl-1-β-D-ribofuranosyl-1(H)-imidazo[4,5-c]pyridine 
• 180253-65-0 (3-methylpyridin-4-yl)carbamic acid tert-butyl ester 
• 1188416-07-0 (S)-N-(2-benzylhexahydro-3H-pyrrolo[1,2-c]imidazol-3-ylidene)-3-methylpyridin-4-amine 
• 152490-14-7 (S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-N-(3-methyl-pyridin-4-yl)-3-phenyl-propionamide 
• 13958-86-6 5-methyl-3,4-pyridinediamine 
• 849777-09-9 [2-(5-chloro-2-fluoro-phenyl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-pyridin-4-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS

The invention relates to substituted bicyclic pyrroloheterocyclyl compounds of general formula (I), wherein A1 and A2 represent direct bond or C(=O), with the proviso that 0 or 1 of A1 and A2 represents C(=O); m and n independently denote 0, 1, 2 or 3, with the proviso that the sum [n + m] is 1, 2, 3 or 4; R1 denotes H, F, CI, Br, I, CN, CF3, CF2H, CFH2, CO2H, CO2R13, R13, OH. O-R13, NH2, N(H)R13, N(R13)2, R2 represents 0 to 4 substituents, each independently selected from F, CI, Br, CN. CF3, CF2H, CFH2, R13, OH, O-R13, NH2, N(H)R13 and N(R13)2; Ar1 represents phenyl or 5- or 6-membered heteroaryl, in each case unsubstituted or substituted with one, two, three or four substituents, independently selected from F, CI, Br, CN, CF3. CF2H, CFH2, R13 and O- R13; or C3-6-cycloalkyl or 3 to 7 membered heterocycloalkyl, in each case unsubstituted or mono- or polysubstituted; Ar2 represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or said heteroaryl may be unsubstituted or mono- or polysubstituted and may be condensed with a 4-, 5-, 6-or 7- membered ring, being carbocyclic or heterocyclic, wherein said condensed ring may be saturated, partially unsaturated or aromatic and may be unsubstituted or mono- or polysubstituted; useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT

The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general Formula (A) wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general Formula and their use in the treatment or prophylaxis of viral infections.

Titanium(0) Reagents. III. - A Convenient Preparation of 4-Pyridinamine Derivatives

-